On its fourth-quarter earnings call Monday, January 28, executives at Biogen Inc. cautioned that a potential spring launch for multiple sclerosis treatment BG-12 might not be quite as robust as analysts anticipate.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?